Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Altria Group Inc — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.32 (market cap $6.04B), while Altria Group Inc trades at $71.7 (market cap $119.25B). The key difference: Altria Group Inc is far larger — about 19.7× Iovance Biotherapeutics Inc. Common Stock's market cap, and Altria Group Inc pays a 6.22% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Altria Group Inc for 154 Days on average.
| IOVA | MO | |
|---|---|---|
Market Cap | $6.04B | $119.25B |
Volume | 14,805,993 | 11,178,169 |
Sector | Health | Consumer Staples |
52-Week High | $14.82 | $74.92 |
52-Week Low | $1.81 | $54.72 |
Typical Hold Time | 0 Days | 154 Days |
Enterprise Value | $5.97B | $141.46B |
Dividend Yield | — | 6.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Altria Group (MO) trades at $69.39, up 1.22% today, near the analyst consensus price target of $69.71. The stock shows a bullish technical trend with strong moving average signals, while oscillators remain neutral. Fundamentally, the company maintains robust profitability with a 39% net income margin and strong cash flow, though revenue has been slightly declining. Recent earnings have been mixed, with one beat and two misses in the last three quarters. A high dividend yield of approximately 6.6% is supported by 60 consecutive annual increases, but the balance sheet shows negative shareholder equity.
The outlook for MO balances income appeal against structural challenges. The high dividend and bullish analyst consensus (61.5% buy ratings) offer value for income investors, but risks include declining core tobacco sales, regulatory pressures on nicotine products, and a leveraged balance sheet. Earnings growth and smoke-free product adoption are critical for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
